Ownership and insider activity for Rezolute, Inc. (RZLT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsu...
Price
| Price | $3.98 |
| Market Cap | $383M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-02 | Karnawat Sunil Ratilal | F-InKind | 2,267 | $10K |
| 2026-07-02 | ROBERTS BRIAN KENNETH | F-InKind | 3,062 | $15K |
| 2026-07-02 | Elam Nevan C | F-InKind | 8,004 | $40K |
| 2026-07-02 | Evans Daron | F-InKind | 3,062 | $15K |
| 2026-03-30 | Evans Daron | P-Purchase | 10,000 | $28K |
| 2026-03-02 | ROBERTS BRIAN KENNETH | F-InKind | 11,439 | $34K |
| 2026-03-02 | Evans Daron | F-InKind | 11,438 | $34K |
| 2026-03-02 | Elam Nevan C | F-InKind | 27,618 | $83K |
| 2025-12-16 | Hogenhuis Wladimir | P-Purchase | 5,650 | $10K |
| 2025-12-16 | ROBERTS BRIAN KENNETH | P-Purchase | 28,000 | $48K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.1M | $4.5M | $1.6M | $11.6M | $10.0M | $41.0M | $150.4M | $16.0M | $70.4M | $94.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $85.9M | $56.5M | $73.8M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $4.5M | $4.9M | $2.0M | $12.1M | $10.5M | $42.0M | $152.1M | $104.9M | $128.7M | $171.1M |
| Property, Plant & Equipment | $6.0M | $5.3M | $368374 | $44000 | $416000 | $425000 | $168000 | $2.2M | $2.0M | $1.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $51614 | $44322 | $37030 | $29000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $10.9M | $10.6M | $2.5M | $12.3M | $11.0M | $42.6M | $152.4M | $123.7M | $132.7M | $175.5M |
| Accounts Payable | $1.5M | $926039 | $1.7M | $563000 | $893000 | $1.0M | $1.1M | $3.3M | $4.9M | $5.8M |
| Short-term Debt | $83128 | $10000 | $3.4M | $10000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.7M | $1.8M | $6.2M | $8.4M | $3.2M | $2.0M | $2.5M | $5.2M | $9.6M | $11.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $14.0M | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.1M | $2.1M | $6.5M | $10.5M | $3.6M | $16.5M | $2.9M | $7.5M | $11.7M | $13.4M |
| Retained Earnings | -$44.0M | -$64.3M | -$94.2M | -$126.9M | -$147.2M | -$168.1M | -$209.2M | -$261.0M | -$329.4M | -$403.9M |
| Total Equity | $8.8M | $8.5M | -$4.0M | $1.8M | $7.4M | $26.1M | $149.5M | $116.2M | $121.0M | $162.1M |
| Total Debt | $83128 | $10000 | $3.4M | $10000 | $410000 | $14.4M | $188000 | $2.5M | $2.2M | $1.6M |
| Net Debt | -$4.0M | -$4.5M | $1.8M | -$11.6M | -$9.5M | -$26.6M | -$150.2M | -$99.4M | -$124.6M | -$166.2M |
| Working Capital | $2.8M | $3.2M | -$4.2M | $3.8M | $7.3M | $40.0M | $149.6M | $99.7M | $119.0M | $159.2M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 15.84 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 11.58 |
Profitability
| Return on Equity | -58.82% |
| Return on Invested Capital | -73.68% |
| Return on Assets | -64.95% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: DAWN · EYPT · GERN · KURA · MRVI · NBTX · PRME
Explore sector: Healthcare · Biotechnology
More sections of RZLT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks